Why Is Stelara So Hard to Find? [Explained for 2026]

If you've been prescribed Stelara (ustekinumab) and run into roadblocks at the pharmacy, you're not alone. Despite being one of the world's best-selling biologic drugs — generating $10.4 billion in annual sales as recently as 2024 — Stelara remains frustratingly difficult for many patients to access. In 2026, a combination of specialty pharmacy requirements, insurance barriers, and a rapidly shifting biosimilar landscape makes finding Stelara feel like navigating a maze.

This guide breaks down the real reasons Stelara is hard to find, what's changed in 2026, and what you can do to get your prescription filled faster.

What Is Stelara and Why Is It Prescribed?

Stelara is a biologic injection manufactured by Janssen Biotech (Johnson & Johnson). It works by blocking two proteins — interleukin-12 (IL-12) and interleukin-23 (IL-23) — that drive inflammation in autoimmune conditions. It's FDA-approved for moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.

Unlike standard medications you pick up at a local chain pharmacy, Stelara is a specialty medication — a category that comes with its own unique set of access challenges.

Reason #1: Stelara Is a Specialty Medication — Not Available at Every Pharmacy

Specialty medications like Stelara require cold storage, specialized handling, and often must be dispensed through a specialty pharmacy — not your neighborhood CVS or Walgreens. While some major chains have specialty pharmacy arms, many standard pharmacy locations simply cannot fill a Stelara prescription.

Common specialty pharmacies that carry Stelara and its biosimilars include Accredo, CVS Specialty, Walgreens Specialty, and Optum Specialty Pharmacy. But even within these networks, availability and wait times can vary significantly depending on your insurance plan and location.

Reason #2: Prior Authorization and Step Therapy Requirements

One of the biggest barriers to getting Stelara is insurance. Most insurance plans — roughly 96% — do cover Stelara, but the majority require prior authorization (PA) before they'll pay for it. Many also require step therapy, meaning you may need to try and fail on less expensive treatments before your insurer will approve a biologic like Stelara.

Prior authorization processes can take anywhere from a few days to several weeks. During that waiting period, patients are often left without access to a critical medication. If a PA is denied, an appeals process adds even more time.

Reason #3: The Biosimilar Transition Is Creating Confusion in 2026

Stelara's patents expired in September 2023, and beginning in January 2025, a wave of biosimilar versions hit the US market. By 2026, eight FDA-approved ustekinumab biosimilars exist — including Wezlana, Selarsdi, Pyzchiva, Yesintek, Otulfi, Imuldosa, Steqeyma, and Starjemza. These are priced 80-95% below brand-name Stelara.

While this is great news for long-term affordability, the rapid shift has created real-world access problems in the short term. Many insurers are actively moving patients from brand-name Stelara to biosimilar versions. If your prescription says "Stelara" but your plan now only covers a biosimilar — or vice versa — it can cause delays, confusion at the pharmacy, and coverage denials.

In fact, a survey representing 83% of commercial insurance lives found that the majority of payers were very or extremely likely to remove brand Stelara from their formularies by Q2 2026 in favor of biosimilar alternatives.

Reason #4: Exclusive Pharmacy Deals Lock Out Many Patients

Several of the new ustekinumab biosimilars are tied to exclusive pharmacy networks. For example, Amgen's Wezlana — the first ustekinumab biosimilar to launch — is only available through Optum, a division of UnitedHealth Group. If you don't have a UnitedHealth plan or access to Optum's pharmacy, you simply cannot get Wezlana, even if that's what your insurer prefers.

Other PBMs (pharmacy benefit managers) including CVS/Caremark and Express Scripts have their own preferred ustekinumab products, further fragmenting access based on who your insurer uses for pharmacy benefits.

Reason #5: High Cash Price Makes Out-of-Pocket Access Nearly Impossible

Without insurance, a single dose of brand-name Stelara (45 mg prefilled syringe) can cost over $21,000 at retail. Even with a GoodRx coupon, prices typically range from $7,000–$11,000 per dose. This makes cash-pay access virtually impossible for most patients, meaning insurance coverage — and the prior authorization process that comes with it — is essentially mandatory.

Biosimilar options like Yesintek launch at around $3,000 WAC — still expensive, but 80-90% lower than Stelara brand pricing. Most biosimilars also offer $0 copay programs for commercially insured patients.

Is There an Official Stelara Shortage in 2026?

No — as of 2026, the FDA has not listed Stelara or ustekinumab biosimilars on its official drug shortage list. The product itself is being manufactured. However, the access challenges described above — specialty pharmacy requirements, insurance prior authorizations, PBM-restricted distribution, and the brand-to-biosimilar transition — create real-world shortages for individual patients even when supply is technically available.

This means that your ability to fill a Stelara prescription often depends less on whether the drug exists and more on whether the right version is covered by your specific plan, stocked at your designated specialty pharmacy, and approved through prior authorization.

What Can You Do If You Can't Find Stelara?

Here are actionable steps to take right now:

Call your insurance company to confirm which ustekinumab product is covered on your formulary and what PA requirements apply.

Ask your prescriber to initiate a prior authorization immediately — delays here cascade into delays at the pharmacy.

Contact the manufacturer's patient support program (Janssen CarePath / StelarawithMe at 877-227-3728) for assistance with coverage and copay reduction.

Ask your doctor whether a biosimilar version — such as Pyzchiva, Yesintek, or Steqeyma — might be covered more easily by your plan.

[@portabletext/react] Unknown block type "span", specify a component for it in the `components.types` prop

to find which specialty pharmacies near you have ustekinumab in stock — so you're not wasting time calling one pharmacy at a time.

The Bottom Line

Stelara isn't hard to find because it's in shortage — it's hard to find because it exists at the intersection of specialty pharmacy logistics, insurance bureaucracy, and a disruptive biosimilar market transition. Understanding the real barriers is the first step toward getting through them faster.

For step-by-step tips on locating Stelara at a pharmacy near you, check out our guide: How to Find Stelara in Stock Near You (Tools + Tips)